Future Science Group
Browse
supplementary_information_revision.docx (1.5 MB)

Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced RCC.

Download (1.5 MB)
figure
posted on 2022-06-27, 07:34 authored by Jianxin Pang, Peihao Wu, Yanqing Jiang, Junyan Wu, Kaifeng Qiu, Ruizhe Liu

 Figure S1. Kaplan–Meier curves and modelled curves. 

History

Usage metrics

    Immunotherapy

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC